Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial

被引:0
作者
Rondanelli, M. [1 ,2 ]
Gasparri, C. [3 ]
Petrangolini, G. [4 ]
Allegrini, P. [4 ]
Avenoso, D. [4 ]
Fazia, T. [5 ]
Bernardinelli, L. [5 ]
Peroni, G. [3 ]
Patelli, Z. [3 ]
Mansueto, F. [3 ]
Tartara, A. [3 ]
Cavioni, A. [3 ]
Riva, A. [4 ]
机构
[1] Univ Pavia, Dept Publ Hlth Expt & Forens Med, Pavia, Italy
[2] IRCCS Mondino Fdn, Pavia, Italy
[3] Univ Pavia, Azienda Serv Persona, Endocrinol & Nutr Unit, Ist Santa Margherita, Pavia, Italy
[4] Indena SpA, R&D Dept, Milan, Italy
[5] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy
关键词
Berberine; Impaired fasting blood glucose; Phyto-someTM; Insulin; Body composition; RISK; ADULTS; KINASE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
- OBJECTIVE: Berberine is a plant alkaloid known to exert positive metabolic effects. Human studies have confirmed its ability to improve the lipid and glycemic profile. This study aimed to evaluate the potential benefit of oral supplementation of Berberine PhytosomeTM (2 tablets/day, 550 mg/tablet) on the metabolic profile of subjects with impaired fasting blood glucose (IFG). PATIENTS AND METHODS: A total of 49 overweight subjects, 28 females and 21 males, were randomly assigned to either the supplemented group (n=24) or placebo (n=25). We considered glycemia as the primary endpoint and total cholesterol, high-density lipoprotein (HDL), total cholesterol/HLD, low-density lipoprotein (LDL), LDL/HDL, triglycerides, insulin, glycated hemoglobin, Homeostasis Model Assessment (HOMA), ApoA, ApoB, ApoB/ApoA, androgen suppression treatment (AST), alternative lengthening of telomeres (ALT), gamma-glutamyl transferase (GGT), creatinine, and body composition by Dual-energy X-ray Absorptiometry (DXA) as secondary endpoints. These parameters have been assessed at baseline, after 30 days, and after 60 days. RESULTS: After two months of treatment, through the use of linear mixed effect models, a statistically significant difference between supplemented and placebo groups was observed for glycemia [13=-0.2495% C.I. (-0.47;-0.06), p=0.004], total cholesterol [13=-0.25, 95% C.I. (-0.45;-0.04), p=0.05], total cholesterol/HDL [13=0.25, 95% C.I. (-0.43;-0.06), p=0.04], triglycerides [13=-0.14, 95% C.I. (-0.25;-0.02), p=0.05], insulin [13=-1.78, 95% C.I. (-2.87;-0.66), p=0.009], ApoB/ ApoA [13=-0.08, 95% C.I. (-0.13;-03), p=0.004], Visceral adipose tissue (VAT) [13=-91.50, 95% C.I. (-132.60;-48.19), p<0.0001] and fat mass [13=945.56, 95% C.I. (-1,424.42;-441.57), p=0.004]. CONCLUSIONS: The use of berberine had no adverse events, supporting its use as a natural alternative to pharmacological therapies in the case of IFG.
引用
收藏
页码:6718 / 6727
页数:10
相关论文
共 50 条
[1]   Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol® on glycemic control of subjects with impaired fasting glucose [J].
Evans, Malkanthi ;
Judy, William V. ;
Wilson, Dale ;
Rumberger, John A. ;
Guthrie, Najla .
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 :275-285
[2]   Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial [J].
Panigrahi, Antarmayee ;
Mohanty, Susant .
BMC ENDOCRINE DISORDERS, 2023, 23 (01)
[3]   Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial [J].
Higashikawa, F. ;
Noda, M. ;
Awaya, T. ;
Danshiitsoodol, N. ;
Matoba, Y. ;
Kumagai, T. ;
Sugiyama, M. .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2016, 70 (05) :582-587
[4]   Effect of Barley on Postprandial Blood Glucose Response and Appetite in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial [J].
Kim, In-Sook ;
Park, Soo-yeon ;
Park, Min Ju ;
Kim, Kyeong Jin ;
Kim, Ji Yeon .
NUTRIENTS, 2024, 16 (22)
[5]   Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study [J].
Bone, Henry G. ;
Lindsay, Robert ;
McClung, Michael R. ;
Perez, Alfonso T. ;
Raanan, Marsha G. ;
Spanheimer, Robert G. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (12) :4691-4701
[6]   JinqiJiangtang tablets for prediabetes: A randomized, double-blind and placebo-controlled clinical trial [J].
Wang, Hui ;
Guo, Liping ;
Shang, Hongcai ;
Ren, Ming ;
Wang, Xuemei ;
Wang, Dehui ;
Chen, Jianzong ;
Li, Shuanglei ;
Chen, Liming ;
Wang, Yue ;
Liu, Zhi ;
Zhai, Jingbo ;
Song, Yuzhen ;
Cao, Hongbo ;
Zhang, Junhua ;
Liu, Chunxiang ;
Sun, Xiao ;
Huo, Da ;
Mu, Wei ;
Zhang, Li ;
Zheng, Wenke ;
Yan, Xiaoyan ;
Yao, Chen .
SCIENTIFIC REPORTS, 2017, 7
[7]   The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial [J].
Li, Meijuan ;
Liu, Ying ;
Qiu, Yuying ;
Zhang, Jing ;
Zhang, Yonghui ;
Zhao, Yongping ;
Jia, Qiong ;
Li, Jie .
PSYCHIATRY RESEARCH, 2021, 300
[8]   Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial [J].
Antarmayee Panigrahi ;
Susant Mohanty .
BMC Endocrine Disorders, 23
[9]   Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial [J].
Zhao, Ying ;
Yang, Yuan-Yuan ;
Yang, Bao-Lin ;
Du, Ya-Wei ;
Ren, Da-Wei ;
Zhou, Hong-Mei ;
Wang, Jing ;
Yang, Hui-Min ;
Wang, Yao-Xian ;
Zhang, Ying-Ying ;
Wu, Sheng-Xian .
TRIALS, 2021, 22 (01)
[10]   Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial [J].
Ying Zhao ;
Yuan-Yuan Yang ;
Bao-Lin Yang ;
Ya-Wei Du ;
Da-Wei Ren ;
Hong-Mei Zhou ;
Jing Wang ;
Hui-Min Yang ;
Yao-Xian Wang ;
Ying-Ying Zhang ;
Sheng-Xian Wu .
Trials, 22